<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title xml:lang="eng">Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome</dc:title>
  <dc:language>eng</dc:language>
  <dc:format>application/pdf</dc:format>
  <dc:creator>Catello Giordano</dc:creator>
  <dc:creator>Jonatan Kendler</dc:creator>
  <dc:creator>Maximilian Sexl</dc:creator>
  <dc:creator>Sebastian Kollman</dc:creator>
  <dc:creator>Maxim Varenicja</dc:creator>
  <dc:creator>Boglárka Szabó</dc:creator>
  <dc:creator>Gerald Timelthaler</dc:creator>
  <dc:creator>Dominik Kirchhofer</dc:creator>
  <dc:creator>Oldamur Hollóczki</dc:creator>
  <dc:creator>Suzanne D. Turner</dc:creator>
  <dc:creator>Richard Moriggl</dc:creator>
  <dc:creator>Lukas Kenner</dc:creator>
  <dc:creator>Mohamed Touaibia</dc:creator>
  <dc:creator>Olaf Merkel</dc:creator>
  <dc:subject xml:lang="eng">Humans</dc:subject>
  <dc:subject xml:lang="eng">Caffeic Acids Pharmacology</dc:subject>
  <dc:subject xml:lang="eng">Caffeic Acids Chemistry</dc:subject>
  <dc:subject xml:lang="eng">Phenylethyl Alcohol Analogs &amp; Derivatives</dc:subject>
  <dc:subject xml:lang="eng">Phenylethyl Alcohol Pharmacology</dc:subject>
  <dc:subject xml:lang="eng">Phenylethyl Alcohol Chemistry</dc:subject>
  <dc:subject xml:lang="eng">Centrosome Drug Effects</dc:subject>
  <dc:subject xml:lang="eng">Centrosome Metabolism</dc:subject>
  <dc:subject xml:lang="eng">Antineoplastic Agents Pharmacology</dc:subject>
  <dc:subject xml:lang="eng">Antineoplastic Agents Chemistry</dc:subject>
  <dc:subject xml:lang="eng">Apoptosis Drug Effects</dc:subject>
  <dc:subject xml:lang="eng">Cell Line, Tumor</dc:subject>
  <dc:subject xml:lang="eng">Cell Proliferation Drug Effects</dc:subject>
  <dc:type xml:lang="eng">Text</dc:type>
  <dc:type xml:lang="eng">journal article</dc:type>
  <dc:type xml:lang="ita">Testo</dc:type>
  <dc:type xml:lang="ita">Articolo di rivista</dc:type>
  <dc:description xml:lang="eng">Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma affecting children and young adults. About 30% of patients develop therapy resistance therefore new precision medicine drugs are highly warranted. Multiple rounds of structure-activity optimization of Caffeic Acid Phenethyl Ester have resulted in CM14. CM14 causes upregulation of genes involved in oxidative stress response and downregulation of DNA replication genes leading to G2/M arrest and subsequent apoptosis induction. In accordance with this, an unbiased proteomics approach, confocal microscopy and molecular modeling showed that TUBGCP2, member of the centrosomal ?-TuRC complex, is a direct interaction partner of CM14. CM14 overcomes ALK inhibitor resistance in ALCL and is also active in T-cell Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia. Interestingly, CM14 also induced cell death in docetaxel-resistant prostate cancer cells thus suggesting an unexpected role in solid cancers. Thus, we synthesized and thoroughly characterized a novel TUBGCP2 targeting drug that is active in ALCL but has also potential for other
malignancies.</dc:description>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:publisher>Elsevier</dc:publisher>
  <dc:type xml:lang="deu">Text</dc:type>
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
  <dc:identifier>doi:10.1016/j.redox.2025.103582</dc:identifier>
  <dc:rights xml:lang="eng">Copyright © 2025 The Authors</dc:rights>
  <dc:rights xml:lang="eng">open access</dc:rights>
  <dc:source xml:lang="eng">Redox Biology</dc:source>
  <dc:date>2025</dc:date>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:4027</dc:identifier>
</oai_dc:dc>